Garnier Tracy, Croft Simon L
Department of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, UK.
Curr Opin Investig Drugs. 2002 Apr;3(4):538-44.
Parenteral pentavalent antimonials remain the standard therapy for cutaneous leishmaniasis. More effective and patient-compliant topical treatments are an important alternative treatment for the localized self-limiting forms of this disease. Two paromomycin ointments are commercially available but their use is limited by either toxicity or lack of efficacy. Other topical formulations have been in clinical trials, but many results have been equivocal and no major breakthroughs have been achieved. The focus of this review is on recent developments in the field of topical treatment for cutaneous leishmaniasis and rational approaches to enhance topical drug absorption.
肠胃外五价锑剂仍然是皮肤利什曼病的标准疗法。对于这种疾病的局限性自限性形式，更有效且患者依从性更好的局部治疗是一种重要的替代疗法。有两种巴龙霉素软膏可供商业使用，但它们的使用受到毒性或疗效不佳的限制。其他局部用制剂已进入临床试验，但许多结果并不明确，尚未取得重大突破。本综述的重点是皮肤利什曼病局部治疗领域的最新进展以及增强局部药物吸收的合理方法。
